Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?
about
Preclinical development of monoclonal antibodies: considerations for the use of non-human primatesA comparison of the effects of three GM corn varieties on mammalian healthPractical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesShould preclinical studies be registered?Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.Nonclinical development of a biosimilar: the current landscape.Long-term systemic toxicity of shikonin derivatives in Wistar rats.
P2860
Q24655266-60BB35DE-C9A9-44CF-AC3D-122D416B1E75Q24657967-968C3F3B-0C2D-4134-9C4C-31D39CF59127Q27690917-5942F7D7-436A-4858-94E3-E8B61135D3DFQ35893083-1275EF9C-5F0B-4A62-A294-71E50C45068FQ37753534-A79DF605-74F2-43E4-8F54-3BBB5892001AQ37795414-0CF60E34-A5DF-4808-8FD5-761F6664C7D7Q37947551-73D166F3-9152-4490-BACC-6A3F6A28C288Q38088303-5749284B-789B-4FBF-88F0-0703BF72AA6FQ38093368-DC2E46CC-F80D-45D2-849D-8E06B53330BCQ38208275-65E491C6-26F4-4B23-AB5C-B0F464F28CEEQ38687397-D661E3D9-D1B8-4F64-AE23-6E03856427B7Q39464414-A0260DB0-76A6-4F6A-9E16-E814F4521DDFQ54659304-F965E6E0-E762-45ED-9C09-7AC58FE7606A
P2860
Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Duration of chronic toxicity s ...... is 6 months still appropriate?
@en
type
label
Duration of chronic toxicity s ...... is 6 months still appropriate?
@en
prefLabel
Duration of chronic toxicity s ...... is 6 months still appropriate?
@en
P2093
P1476
Duration of chronic toxicity s ...... is 6 months still appropriate?
@en
P2093
Barbara Mounho
Christopher Hurst
Janet Clarke
John Vahle
Joy Cavagnaro
Laura Andrews
Pauline Martin
Rafael Ponce
Shawn Heidel
Theresa Reynolds
P356
10.1016/J.YRTPH.2007.08.001
P407
P577
2007-08-24T00:00:00Z